Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease.

Activation of sphingosine kinase (SK) is a key response to many inflammatory processes. The present studies test the hypothesis that an orally available SK inhibitor, ABC294640, would be effective in rodent models of Crohn's disease.
Trinitrobenzene sulfonic acid (TNBS) was administered rectally to mice and rats. Rats were treated with ABC294640 orally alone or in combination with olsalazine and disease progression was monitored.
For both rodent species, treatment with ABC294640 attenuated disease progression. Colon samples from the ABC294640-treated animals had improved histology and cytokine parameters when compared with vehicle-treated animals. The expression of SK was similarly increased in TNBS-treated animals and in human colon tissue specimens from inflammatory bowel disease patients relative to normal, control patients.
Sphingosine kinase may be a critical mediator of colonic damage during intestinal inflammation, and pharmacologic inhibitors of this enzyme may prove useful in the treatment of Crohn's disease.
AuthorsLynn W Maines, Leo R Fitzpatrick, Cecelia L Green, Yan Zhuang, Charles D Smith
JournalInflammopharmacology (Inflammopharmacology) Vol. 18 Issue 2 Pg. 73-85 (Apr 2010) ISSN: 1568-5608 [Electronic] Switzerland
PMID20151210 (Publication Type: Journal Article)
Chemical References
  • Aminosalicylic Acids
  • Enzyme Inhibitors
  • Gastrointestinal Agents
  • Interleukin-1beta
  • Pyridines
  • Tumor Necrosis Factor-alpha
  • Trinitrobenzenesulfonic Acid
  • Prednisolone
  • 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
  • Peroxidase
  • Phosphotransferases (Alcohol Group Acceptor)
  • sphingosine kinase
  • Adamantane
  • olsalazine
  • Adamantane (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
  • Aminosalicylic Acids (administration & dosage, pharmacology, therapeutic use)
  • Animals
  • Body Weight (drug effects)
  • Colon (drug effects, enzymology, metabolism, pathology)
  • Crohn Disease (chemically induced, drug therapy, metabolism, pathology)
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Enzyme Inhibitors (pharmacology, therapeutic use)
  • Epithelial Cells (enzymology, metabolism)
  • Female
  • Gastrointestinal Agents (administration & dosage, pharmacology, therapeutic use)
  • Humans
  • Interleukin-1beta (metabolism)
  • Leukocytes (enzymology, metabolism)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neutrophils (enzymology, pathology)
  • Peroxidase (metabolism)
  • Phosphotransferases (Alcohol Group Acceptor) (antagonists & inhibitors, metabolism)
  • Prednisolone (administration & dosage, pharmacology, therapeutic use)
  • Pyridines (administration & dosage, pharmacology, therapeutic use)
  • Rats
  • Rats, Sprague-Dawley
  • Treatment Outcome
  • Trinitrobenzenesulfonic Acid (administration & dosage, pharmacology)
  • Tumor Necrosis Factor-alpha (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: